Search
Now showing items 101-110 of 111
Mortality in psychotic depression: 18-year follow-up study
(2022-10)
Background
Evidence on the role of co-occurring psychiatric disorders in mortality associated with psychotic depression is limited.
Aims
To estimate the risk of cause-specific mortality in psychotic depression compared ...
A co-produced online cultural experience compared to a typical museum website for mental health in people aged 16-24: A proof-of-principle randomised controlled trial
(2022-09)
Objective: We aimed to compare a co-produced online intervention encompassing the diverse human stories behind art and artefacts, named Ways of Being (WoB), with a typical museum website, the Ashmolean (Ash) on negative ...
Childhood determinants of past-year anxiety and depression in recently transitioned military personnel
(2020-05)
Background: Anxiety and depression may hamper a smooth transition from military to civilian life and may be important predictors of longer-term health and functioning. However, it is as yet unclear to what extent they are ...
Effect of selective serotonin reuptake inhibitor treatment following diagnosis of depression on suicidal behaviour risk: a target trial emulation
(2023-07)
There is concern regarding the impact of selective serotonin reuptake inhibitors (SSRIs) on suicidal behaviour. Using the target trial framework, we investigated the effect on suicidal behaviour of SSRI treatment following ...
Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder
(2023-07)
JNJ-54175446 is a selective purine P2X7 receptor (P2X7R) antagonist that attenuates microglial IL-1β/IL-18 release. In healthy volunteers, JNJ-54175446 suppressed peripheral interleukin (IL)-1β release, and attenuated ...
Translating the promise of 5HT4 receptor agonists for the treatment of depression
(2020-02)
Animal experimental studies suggest that 5-HT4 receptor activation holds promise as a novel
target for the treatment of depression and cognitive impairment. 5-HT4 receptors are postsynaptic
receptors that are located in ...
Pro-dopaminergic pharmacological interventions for anhedonia in depression: protocol for a living systematic review of human and non-human studies
(2023-10)
Anhedonia is a key symptom of depression, and it has been suggested as a potential target for future individualised treatments. However, much is unknown about how interventions enhancing dopaminergic pathways may affect ...
Pramipexole for the Treatment of Depression: Efficacy and Mechanisms
(2023-11)
Dopaminergic mechanisms are a plausible treatment target for patients with clinical depression but are relatively underexplored in conventional antidepressant medications. There is continuing interest in the potential ...
Towards precision in the diagnostic profiling of patients: leveraging symptom dynamics in the assessment of major depressive disorder
(2023-08)
Major depressive disorder (MDD) is a heterogeneous mental disorder. International guidelines present overall symptom severity as the key dimension for clinical characterisation. However, additional layers of individual ...
Cognitive predictors of stress-induced mood malleability in depression
(2023-09)
Basic attentional control, negative biases in attention and interpretation, and rumination are all cognitive processes associated with depression; however, less is known about their predictive role in depressive mood ...